Arbutus Biopharma Corporation
ABUSNASDAQHealthcare● Active
$4.23
$-0.02(-0.44%)
Market Cap$835861066
P/E Ratio—
52W High$5.1
52W Low$3.04
Arbutus Biopharma Corporation (ABUS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ABUS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $14.08M | $6.17M | $18.14M | $39.02M | $10.99M |
| Cost of Revenue | $0.36M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $13.72M | $6.17M | $18.14M | $39.02M | $10.99M |
| Gross Margin %(computed) | 97.42% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $25.24M | $54.04M | $73.70M | $84.41M | $65.50M |
| G&A Expenses | $15.89M | $22.11M | $22.48M | $17.83M | $17.14M |
| Total Operating Expenses | $40.77M | $82.49M | $96.24M | $104.47M | $84.51M |
| Operating Income | ($27.05M) | ($76.32M) | ($78.10M) | ($65.46M) | ($73.52M) |
| Operating Margin %(computed) | -192.08% | — | -430.53% | -167.75% | -669.11% |
| Interest Income | $4.07M | $6.58M | $5.69M | $2.19M | $0.13M |
| Interest Expense | $0.10M | $0.14M | $0.46M | $1.73M | $2.86M |
| Income Before Tax | ($33.50M) | ($69.92M) | ($72.85M) | ($65.01M) | ($76.25M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $4.44M | $0.00M |
| Net Income | ($33.50M) | ($69.92M) | ($72.85M) | ($69.46M) | ($76.25M) |
| Net Margin %(computed) | -237.88% | — | -401.57% | -178.01% | -693.91% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.73 |
| Wtd Avg Shares | 191.60M | 185.61M | 165.96M | 150.94M | 106.24M |
| EBITDA | ($26.69M) | ($68.40M) | ($70.99M) | ($61.86M) | ($71.64M) |
| EBITDA Margin %(computed) | -189.51% | — | -391.30% | -158.54% | -651.96% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Arbutus Biopharma Corporation data
About Arbutus Biopharma Corporation (ABUS) Income Statement
Arbutus Biopharma Corporation (ABUS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ABUS reported revenue of $0.01B, gross profit of $0.01B (gross margin 97.42%), and net income of ($0.03B) — a net profit margin of -237.88%.
Frequently asked questions
ABUS · 4 questionsArbutus Biopharma Corporation (ABUS) reported revenue of $0.01B for 2025, up 128.2% year-over-year.
ABUS revenueABUS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08